The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale AMERICAN HEART JOURNAL Harrington, R. A., Van de Werf, F., Armstrong, P. W., Aylward, P., Veltri, E., Mahaffey, K. W., Moliterno, D. J., Strony, J., Wallentin, L., White, H. D., Diaz, R., Huber, K., Nicolau, J. C., Carlos Prieto, J., Isaza, D., Widimsky, P., Grande, P., Nieminen, M., Montalescot, G., Bode, C., Wong, L., Ofner, P., Lewis, B. S., Ambrosio, G., Valgimigli, M., Ogawa, H., Yamaguchi, J., Jukema, J. W., Cornel, J. H., Nordrehaug, J. E., Ruzyllo, W., Providencia, L., Tan, H., Dalby, A., Seung-Jung, P., Betriu, A., Cequier, A., Held, C., Pfisterer, M., Ming-Fong, C., Timurkaynak, T., Storey, R. F., Chen, E., Hudson, M. P., Lincoff, A. M., Morrow, D. A., Tricoci, P., Whellan, D. 2009; 158 (3): 327-U5


The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA*CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features.TRA*CER is a prospective, randomized, double-blind, multicenter, phase III trial with an original estimated sample size of 10,000 subjects. Our primary objective is to demonstrate that SCH 530348 in addition to standard of care will reduce the incidence of the composite of cardiovascular death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization compared with standard of care alone. Our key secondary objective is to determine whether SCH 530348 will reduce the composite of cardiovascular death, MI, or stroke compared with standard of care alone. Secondary objectives related to safety are the composite of moderate and severe GUSTO bleeding and clinically significant TIMI bleeding. The trial will continue until a predetermined minimum number of centrally adjudicated primary and key secondary end point events have occurred and all subjects have participated in the study for at least 1 year. The TRA*CER trial is part of the large phase III SCH 530348 development program that includes a concomitant evaluation in secondary prevention.TRA*CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies.

View details for DOI 10.1016/j.ahj.2009.07.001

View details for Web of Science ID 000269641200002

View details for PubMedID 19699853